Mazdutide (Mazdutide (Dual GLP-1/Glucagon Agonist))
A dual GLP-1/glucagon receptor agonist with promising weight loss results comparable to tirzepatide, including additional hepatic fat reduction.
How it works
Dual activation of GLP-1 receptors for appetite suppression combined with glucagon receptor activation for enhanced hepatic lipid oxidation and energy expenditure.
Key facts
- Molecular weight: 4,300 Da (approximate)
- Half-life: 5-7 days
- Bioavailability: High (SubQ)
- Storage: Refrigerated 2-8°C.
Dosing overview
- Typical dose: 3-9 mg
- Frequency: Once weekly
- Duration: Ongoing
- Route: Subcutaneous
Reported benefits
- Significant weight loss (up to 18%)
- Liver fat reduction
- Improved insulin sensitivity
- Once-weekly convenience
- Potential MASH benefit
Possible side effects
- Nausea
- Diarrhea
- Decreased appetite
- Injection site reactions
Research
- Phase 3 mazdutide for obesity in Chinese adults (2024): Mazdutide 9mg produced 17.3% weight loss at 48 weeks with improved metabolic parameters.
- Mazdutide effects on hepatic steatosis (2023): 60-70% reduction in hepatic fat content measured by MRI-PDFF at 24 weeks.
Compare Mazdutide
Community discussions about Mazdutide
- First 3 weeks on Mazdutide – weight, appetite and HRV notes - 6 comments
- My 8‑week Mazdutide titration – what to expect with nausea and liver fat loss - 6 comments
- Mazdutide first dose nerves, does nausea get better after the first few weeks? - 4 comments
- Mazdutide injection site swelling: what worked for me? - 4 comments
- Mazdutide week 6 nausea and injection site reaction log - 4 comments
- Ask the community about Mazdutide
Research and educational reference only. Not medical advice.